Table 1.
Demographic and clinicopathologic characteristics of study cohort.*
| N (%) | ||
|---|---|---|
|
| ||
| Age at diagnosis (years) | <60 | 16 (23) |
| 60–75 | 40 (56) | |
| >75 | 15 (21) | |
| Race | White | 66 (93) |
| Black | 3 (4) | |
| Other | 2 (3) | |
| BMI (kg/m2) | <25 | 21 (30) |
| 25–30 | 16 (23) | |
| >30 | 32 (46) | |
| Menopausal status | Premenopausal | 1 (1) |
| Postmenopausal | 69 (97) | |
| Unknown | 1 (1) | |
| Tobacco use | Never | 54 (76) |
| Current | 4 (6) | |
| Former | 10 (14) | |
| History of HRT use | Yes | 6 (8) |
| History of OCP use | Yes | 7 (10) |
| Medical comorbidities | ||
| >2 comorbidities | 24 (34) | |
| History of diabetes | 14 (20) | |
| History of hypertension | 38 (54) | |
| History of renal disease | 3 (4) | |
| History of pulmonary disease | 10 (14) | |
| Type of surgery | ||
| Open | 22 (31) | |
| Laparoscopic | 46 (65) | |
| LAVH/TVH | 3 (4) | |
| Histology | ||
| Pure clear cell | 39 (55) | |
| Mixed clear cell | 32 (45) | |
| p53 mutation | ||
| Yes | 16 (23) | |
| No | 16 (23) | |
| Not assessed | 39 (55) | |
| LVSI | Positive | 22 (31) |
| Peritoneal cytology | ||
| Negative | 58 (87) | |
| Atypical | 2 (3) | |
| Positive | 7 (10.0) | |
| FIGO stage | ||
| IA | 54 (76) | |
| IB | 12 (17) | |
| II | 5 (7) | |
| Lymph node assessment | 63 (88.7) | |
| Sentinel LN | 22 (31) | |
| Pelvic LN | 63 (89) | |
| Assessed ≥ 4 pelvic LN | 51 (72) | |
| Assessed ≥ 3 para-aortic LN | 16 (23) | |
| Adjuvant therapy | Any | 58 (82) |
| Chemotherapy | 43 (61) | |
| Radiation therapy | 50 (70) | |
| Both | 35 (49) | |
| Type of chemotherapy | ||
| Carboplatin/taxane | 41 (95) | |
| Carboplatin alone | 1 (2) | |
| Cisplatin (chemosensitizing) | 1 (2) | |
| Type of radiation therapy | ||
| VBT | 32 (64) | |
| EBRT | 2 (4) | |
| VBT and EBRT | 16 (32) | |
| Recurrence | ||
| Local | 1 (1) | |
| Regional | 3 (4) | |
| Distant | 3 (4) | |
| Cause of death | ||
| Uterine cancer | 4 (6) | |
| Other | 3 (4) | |
| Unknown | 2 (3) | |
*
Categories may not sum to 100% due to missing data.